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Abstract
Purpose—Few studies have investigated the role of race in the association of diabetes and 
obesity with prostate cancer aggressiveness. Here we evaluate the independent association 
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between diabetes and obesity with prostate cancer aggressiveness in White Americans and Black 
Americans.
Methods—Our cross-sectional, case-only study consisted of 1058 White Americans and 991 
Black Americans from the North Carolina-Louisiana Prostate Cancer (PCaP) project. Diabetes 
status was determined by self-report. Obesity was determined using body mass index and 
calculated based on anthropometric measurements. High aggressive prostate cancer was defined as 
Gleason sum ≥8, or prostate specific antigen >20 ng/ml, or Gleason sum =7 and clinical stage cT3-
cT4. The association between diabetes and obesity with high aggressive prostate cancer at 
diagnosis was evaluated using multivariable logistic regression and adjusted for potential 
confounders.
Results—Diabetes was not associated with high aggressive prostate cancer in the overall sample 
(OR: 1.04; 95% CI: 0.79, 1.37), White Americans (OR: 1.00; 95% CI: 0.65, 1.57), or Black 
Americans (OR: 1.07; 95% CI: 0.75, 1.53). Obesity, independent of diabetes, was positively 
associated with high aggressive prostate cancer in White Americans (OR: 1.98; 95% CI: 1.14, 
3.43), but not in the overall sample (OR: 1.37; 95% CI: 0.99, 1.92) or Black Americans (OR: 1.09; 
95% CI: 0.71, 1.67).
Conclusions—Diabetes was not associated with prostate cancer aggressiveness, overall, or in 
either race-group. Obesity, independent of diabetes, was associated with high aggressive prostate 
cancer only in White Americans.
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Introduction
Prostate cancer (CaP) is the most common incident cancer among men in the United States. 
The Surveillance Epidemiology and End Results (SEER) reported that, 14% of men will be 
diagnosed with CaP during their lifetime [1]. An estimated 180,890 new cases of CaP and 
26,120 CaP deaths occurred in the United States during 2016 [2]. CaP is a disease of 
disparities. Black Americans (Blacks) are more likely to be diagnosed with and die from 
CaP than White Americans (Whites). The incidence of CaP from 2008-2012 is higher in 
Blacks at 214.5 cases per 100,000 compared to 130.4 cases per 100,000 in Whites [1]. The 
age-adjusted death rate in Blacks was more than double that in Whites between 2008-2012 
[1].
Numerous studies have shown that diabetes is associated with a reduced risk of incident CaP 
[3-10]. Insulin is a known growth factor for CaP cells [11,12]. Thus diabetics, with 
potentially lower levels of circulating insulin, may be less likely to develop CaP [11]. Other 
possible explanations for this inverse association include changing levels of testosterone and 
decreased CaP detection among diabetic men [6,13,14]. Diabetics are more likely to be 
obese than their non-diabetic counterparts [15]. Digital rectal exam (DRE) CaP detection 
and prostate biopsy are both more difficult in obese men, and obese men may have lower 
levels of prostate specific antigen (PSA), any of which could contribute to lower rates of 
CaP diagnosis [6,14,16,17].
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By contrast, studies among men already diagnosed with CaP show that diabetes and obesity 
are positively associated with CaP aggressiveness [13,17-25]. Jayachandran et al. 
hypothesized that the positive association between diabetes and CaP aggressiveness is a 
result of a “selection pressure” where only high aggressive prostate CaP can survive in a 
low-insulin, poor growth environment [13]. In addition, the insulin profile of diabetics 
changes throughout the diabetes disease-course [13,14]. Newly diagnosed diabetics, in 
particular, likely have high insulin levels that create an environment that promotes CaP 
growth [14]. The positive association between diabetes and CaP aggressiveness observed in 
the literature is limited to studies with clinic or hospital-based populations or patients 
undergoing a single treatment type. Few studies have included sufficient numbers of Black 
men to examine the role of race on the diabetes-CaP aggressiveness association, and the two 
existing studies have yielded different results [13,22].
We examined the association of diabetes and obesity, independent of diabetes, with high 
aggressive CaP at diagnosis, defined as a Gleason sum ≥8, or PSA >20 ng/ml, or Gleason 
sum =7 and clinical stage cT3-cT4. This analysis adds to the literature by examining the 
association between diabetes and CaP aggressiveness at diagnosis in racially-diverse sample-
group from the Southern U.S. Specifically, our study population was a large, population-
based sample of men who had incident CaP, were over-sampled for Blacks, were diagnosed 
in the PSA screening era, and participated in the North Carolina-Louisiana Prostate Cancer 
Project (PCaP). This analysis builds on previous PCaP research that found obesity was 
associated with CaP aggressiveness at diagnosis, by accounting for the diabetic status of 
PCaP research subjects [23]. We further expand this research by presenting prevalence 
differences, in addition to odds ratios (ORs).
Methods
Study Population and data collection
PCaP has been described in detail [26]. PCaP is a population-based cross-sectional, case-
only study of research subjects with incident CaP. All research subjects were diagnosed with 
adenocarcinoma of the prostate between July 2004 and August 2009, and were identified 
using state tumor registries. Eligibility criteria for PCaP research subjects included: resident 
of North Carolina or Louisiana- study areas, first diagnosis of histologically confirmed 
adenocarcinoma of the prostate, 40-79 years old at diagnosis, could complete the study 
interview in English, did not live in an institution (i.e. nursing home), not cognitively 
impaired or in a severely debilitated physical state, and not under the influence of alcohol, 
severely medicated, or apparently psychotic at the time of the interview. Moreover, eligible 
men had to self-identify as African American/Black or Caucasian/White in response to the 
open-ended question, “What is your race?”.
PCaP enrolled Blacks and Whites at an equal rate using a randomized recruitment method 
[27]. Participation rates were 62% in North Carolina, 73% in pre-hurricane Katrina 
Louisiana, and 63% in post-hurricane Katrina Louisiana. 1,130 Blacks and 1,128 Whites 
enrolled in PCaP.
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We excluded 25 research subjects that were underweight [body mass index (BMI) < 18.5] 
and 84 research subjects with missing information on the outcome (CaP aggressiveness) 
from our analytic group. Furthermore, 17 research subjects were excluded due to missing 
information on diabetes (4 research subjects responded they did not know their diabetes 
status and 13 research subjects did not have their diabetes status recorded). Additional 
research subjects were excluded due to missing covariate information (CaP screening 
history, body mass index (BMI), or education) (n=83). Our final analytical sample included 
a total of 2049 research subjects (94% of PCaP research subjects with CaP aggressiveness 
defined at diagnosis) of which 1058 were White and 991 were Black. Although Black 
research subjects were more likely to be excluded than White research subjects, the 
distribution of CaP aggressiveness, diabetes, and covariates was similar for Blacks in the full 
PCaP sample and Blacks in the analytic sample.
The primary outcome was high aggressive CaP based on a composite of diagnostic PSA, 
clinical stage and Gleason sum. We also evaluated CaP aggressiveness solely based on 
Gleason sum. The sample consisted of 2207 research subjects (98% of all PCaP research 
subjects) when the analysis was restricted to Gleason sum.
Research subjects who agreed to participate were visited by a Registered Nurse. The nurse 
administered a questionnaire, took biologic samples, and made anthropometric measures 
during an in-home visit. The nurse also obtained informed consent for the interview and 
specimen collection and release of tumor tissue and medical records. The study 
questionnaire included questions on comorbidities (e.g. diabetes), education level, and CaP 
screening history. The average time between CaP diagnosis and the nurse visit in our study 
sample was 4.9 months. The time between the visit and diagnosis was similar in Whites (4.8 
months) and Blacks (5.0 months).
Medical records were requested from the physicians (up to 3) of all consenting research 
subjects for standardized medical record abstraction. Medical record abstraction included 
information regarding physical examinations and laboratory assays at or near diagnosis, 
clinical stage, Gleason sum, PSA measures, and initial CaP treatment.
Outcome, Exposure, and Covariate Measurement
Our primary outcome of interest was a composite measure of CaP aggressiveness at 
diagnosis [26]. High aggressive CaP was defined as Gleason sum ≥8, or PSA >20 ng/ml, or 
Gleason sum =7 and clinical stage cT3-cT4. Low aggressive CaP was defined as Gleason 
sum <7 and clinical stage cT1-cT2 and PSA <10 ng/ml. Other CaP was defined as 
intermediate aggressive. Low aggressive and intermediate aggressive CaP were collapsed 
into a single category in all our analytic models. We also analyzed CaP aggressiveness using 
Gleason sum alone to allow comparison with previous studies. Gleason sum was analyzed as 
a binary variable with high aggressiveness defined as Gleason sum ≥ 7.
Our primary exposures of interest are diabetes and obesity, independent of diabetes. PCaP 
research subjects self-reported diabetes status when asked the question, “Has a doctor or 
other health professional ever told you that you had diabetes or sugar diabetes?”. Responses 
were recoded as “yes”, “no”, “refused”, or “don't know”. Research subjects who did not 
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know their diabetes status or refused to answer were excluded from our analysis (n=17, 
0.8% of all PCaP research subjects). Obesity was determined using body mass index (BMI). 
BMI was calculated using standardized anthropometric measurements at the home visit, and 
research subjects were categorized as normal (BMI 18.5 to <25), overweight (BMI 25 to 
<30), or obese (BMI ≥ 30) using World Health Organization classifications.
Covariates were selected based on known confounders in the literature and to maintain 
consistency with prior PCaP studies and included race, age, CaP screening history, 
education, and study site. Race was based on self-report, and all research subjects were 
categorized as either White or Black. Age was calculated based on age at diagnosis and 
coded as a continuous variable. Education was based on self-report and categorized as less 
than high school, high school graduate or some college, or college graduate and above. 
Study site was categorized as North Carolina or Louisiana. CaP screening history was based 
on self-report and defined as having at least one PSA or Digital Rectal Exam (DRE) prior to 
CaP diagnosis
Statistical Analysis
Logistic regression was used to assess the association of diabetes and BMI with the 
composite binary outcome (aggressive CaP at diagnosis) in our primary analysis. 
Multivariable models were adjusted for race, age, CaP screening history, education, and 
study site. Models were stratified by race to examine race differences and adjusted for age, 
CaP screening history, education, and study site. Because the outcome of high aggressive 
CaP does not meet the rare disease assumption, prevalence ORs obtained from logistic 
regression should not be interpreted as prevalence ratios.
We conducted several sensitivity analyses. First, we ran multivariable models without 
adjustment for BMI, because weight gain may be risk factor for and a result of having 
diabetes. Obesity is known risk factor for diabetes, and diabetics may also gain weight as a 
result of certain diabetes medications [15,28]. Second, we examined the interaction between 
diabetes and CaP screening history, because it is possible that men with diabetes are more 
likely to receive CaP screening as they may have more contact with the healthcare system to 
manage their diabetes. Third, we restricted our analyses only to men that did not receive CaP 
screening. Finally, we stratified by diabetes status to further elucidate the independent effect 
of diabetes and obesity.
In secondary analyses, we modeled Gleason sum ≥ 7 (vs. <7) rather than using our 
composite outcomemeasure of CaP aggressiveness. Logistic regression was used to assess 
the association of diabetes and BMI with our dichotomous Gleason sum variable using the 
same adjustment set as the analysis using our composite outcome. Models were stratified by 
race.
Prevalence differences were calculated to allow for comparisons in the relative frequency of 
high aggressive CaP across races. Prevalence differences were calculated using the method 
suggested by Spiegelman and Hertzmark [29]. Diabetes and BMI were our exposures of 
interest. Models were adjusted for race, age, CaP screening history, education, and study 
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site. Models were stratified by race to examine race differences and adjusted for age, CaP 
screening history, education, and study site.
All analyses were conducted using SAS 9.4 (Cary, NC).
Results
Characteristics of PCaP Research Subjects (Table 1)
The mean age of research subjects at diagnosis was 63 years. The majority of research 
subjects had CaP screening using PSA or DRE prior to CaP diagnosis. Research subjects 
were enrolled in approximately equal numbers in North Carolina and Louisiana. 
Approximately half of research subjects were high school graduates or had some college 
education. PCaP research subjects were more likely to be overweight or obese than normal 
weight. 21.6% of the sample had diabetes, and 17.9% of the sample had high aggressive CaP 
using our composite measure of aggressiveness.
Blacks (n=991) were slightly younger than Whites (n=1058). Whites were more likely than 
Blacks to have undergone CaP screening prior to diagnosis. The CaP screening prevalence in 
research subjects with diabetes (89.5%) and research subjects without diabetes (90.3%) was 
similar. There were approximately equal numbers of Whites and Blacks at each study site. 
Whites were more likely to be college graduates or above, while blacks were more likely to 
have less than a high school education. Blacks were more likely to have diabetes (26.8%) 
than Whites (16.7%), and were more likely to have high aggressive CaP at diagnosis (20.6% 
vs. 15.3%).
Diabetes and Obesity (Table 2)
The OR for diabetes and high aggressive CaP was close to the null after adjustment for age, 
race, CaP screening history, study site, education, and BMI (OR: 1.04; 95% CI: 0.79, 1.37). 
The association of diabetes and high aggressive CaP was similar in race-specific models 
adjusted for age, CaP screening history, study site, education, and BMI among Whites (OR: 
1.00; 95% CI: 0.65, 1.57) or Blacks (OR: 1.07; 95% CI: 0.75, 1.53). Obesity, adjusted for 
diabetes, was associated with an elevated odds of high aggressive CaP in the overall sample 
(OR: 1.37; 95% CI: 0.99, 1.92) and Whites (OR: 1.98; 95% CI: 1.14, 3.43), but not Blacks 
(OR: 1.09; 95% CI: 0.71, 1.67) in adjusted models. Multivariable models without diabetes 
adjustment, showed a similar association between obesity and high aggressive CaP as our 
primary model [Overall (OR: 1.38; 95% CI: 1.00, 1.92), Whites (OR: 1.98; 95% CI: 1.15, 
3.42), or Blacks (OR: 1.10; 95% CI: 0.72. 1.69)].
Sensitivity Analyses
Models not adjusted for BMI in a sensitivity analysis did not show an association between 
diabetes and high aggressive CaP [Overall (OR: 1.10; 95% CI: 0.84, 1.45), Whites (OR: 
1.14; 95% CI: 0.73, 1.76), or Blacks (OR: 1.09; 95% CI: 0.77. 1.55)]. In multivariable 
models with an additional interaction term for diabetes and CaP screening history, no 
significant interaction was observed in the overall sample (p-value for interaction = 0.28), 
Whites (p-value = 0.61), or Blacks (p-value = 0.37). Due to the small number of research 
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subjects that did not receive CaP screening, analyses restricted to non-screened men were 
highly imprecise, although the ORs were further above the null than in the overall sample 
[Non-screened overall (OR: 1.59, 95% CI: 0.77, 3.26); Non-screened Whites (OR: 1.89, 
95% CI: 0.33, 10.70); Non-screened Blacks (OR 1.54, 95% CI: 0.68, 3.47)]. Multivariable 
models stratified by diabetes status, showed no association between obesity and high 
aggressive CaP in diabetics (OR: 1.16, 95% CI: 0.52, 2.59), and were suggestive of a 
positive association in non-diabetics (OR: 1.43, 95% CI: 0.99, 2.06) after adjustment for 
race, age, CaP screening history, study site, and education. To further examine the potential 
association among non-diabetics, we stratified by race. Results were consistent with our 
overall findings, and showed that obesity was associated with high aggressive CaP among 
non-diabetic Whites (OR: 2.48, 95% CI: 1.35, 4.56), but not non-diabetic Blacks (OR: 0.97, 
95% CI: 0.60, 1.57) after adjustment for age, CaP screening history, study site, and 
education. We did not have adequate statistical power to examine the association of obesity 
and high aggressive CaP stratified by race among diabetics only.
Secondary analyses with Gleason sum as our outcome were consistent with analyses using 
the composite outcome of high aggressive CaP. The observed ORs for Gleason sum ≥ 7 (in 
diabetics vs. non-diabetics) were similar for the overall sample (OR: 0.93; 95% CI: 0.75, 
1.16), and race-specific groups [Whites (OR: 0.96, 95% CI: 0.68, 1.34); Blacks (OR 0.92, 
95% CI: 0.69, 1.23)]. Obesity, independent of diabetes, was associated with Gleason sum ≥ 
7 in both the overall sample (OR: 1.36; 95% CI: 1.06, 1.76) and Whites (OR: 1.51; 95% CI: 
1.03, 2.20), but not Blacks (OR: 1.23; 95% CI: 0.87. 1.75).
Prevalence Differences
ORs are interpretable as measures of association and may mask the relative differences in 
prevalence between Whites and Blacks in our case-only study. We calculated prevalence 
differences as an estimate of the relative frequency of high aggressive CaP in Whites and 
Blacks (Table 3). Prevalence differences showed directions of association that were 
consistent with the results based on ORs. Namely, diabetes was not associated with a higher 
prevalence of aggressive CaP in the study sample as a whole, nor in Whites or Blacks after 
adjusting for age, race (overall sample only), CaP screening history, study site, education, 
and BMI. However, obesity, independent of diabetes, was associated with a 7% (PD: 0.07; 
95% CI: 0.01, 0.14) increase in the prevalence of high aggressive CaP in Whites and a 4% 
increased prevalence in the sample as a whole (PD: 0.04; 95% CI: 0.00, 0.09). The 
prevalence difference in Blacks was close to the null (PD: 0.01; 95% CI: -0.06, 0.08), 
although the estimate is imprecise.
Discussion
Self-reported diabetes was not associated with a composite measure of CaP aggressiveness 
at diagnosis in this population-based study of Whites and Blacks with CaP. We did not 
observe any differences in this association between Whites and Blacks. However, we found 
that obesity, independent of diabetes, was associated with high aggressive CaP in Whites 
using our composite measure of CaP aggressiveness.
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Several studies have reported a positive association between diabetes and CaP 
aggressiveness at diagnosis [13,22,24,25]. However, unlike our study, these studies were 
restricted to clinical patient sets receiving a common treatment, with an outcome of Gleason 
sum alone [13,22,24,25]. Moreover, only one of these studies accounted for obesity in their 
analyses [13]. D'Amico et al. reported a positive association between diabetes and Gleason 
sum 8-10 (OR: 1.85, 95% CI: 1.25, 2.74) among radiation patients [25]. Kang et al reported 
that both type 1 diabetes (OR: 2.05, 95% CI: 1.28, 3.27) and type 2 diabetes (OR: 1.58, 95% 
CI: 1.26, 1.99) were associated with Gleason sum 8-10 in another study that used the same 
patient population [24]. Jayachandran et al. reported that diabetes was associated with 
Gleason sum ≥ 7 (OR: 1.73, 95% CI: 1.22, 2.45) among RP patients from the Shared Equal 
Access Regional Cancer Hospital Database (SEARCH) [13]. By contrast, we did not find an 
association between diabetes and our composite outcome of CaP aggressiveness or Gleason 
sum ≥ 7 in our population-based study sample.
Our results were consistent with the Cancer of the Prostate Strategic Urologic Research 
Endeavor (CaPSURE) study. Chan et al. reported that a history of diabetes was not 
associated with higher Gleason score in multivariate analysis [30]. Although Chan et al. is 
not population-based, it is similar to our study in its inclusion of men treated with either 
radiation or RP and use of a self-reported measure of diabetes. However, this study modeled 
diabetes at baseline as the outcome of interest with Gleason score as a covariate in a 
multivariable model, and as such their analytic approach differed from ours[30].
Only two studies examined racial differences among men diagnosed with CaP [13,22]. Mitin 
et al. reported that diabetes was associated with a Gleason sum 8-10 in Blacks (OR: 1.84, 
95% CI: 1.08, 3.13) and nonblacks (OR: 1.59, 95% CI: 1.33, 1.89) treated with radiation 
[22]. By contrast, Jayachandran et al. reported that diabetes was associated with high-grade 
disease (Gleason sum ≥ 7) in Whites (OR: 2.28, 95% CI: 1.33, 3.91), but not Blacks (OR: 
1.45, 95% CI: 0.90, 2.23) treated with RP [13]. Our results did not show a positive 
association between diabetes and our composite measure of high aggressive CaP in either 
Whites or Blacks. Secondary analyses with Gleason sum ≥7 as our outcome were consistent 
with our CaP aggressiveness composite outcome, and we did not observe an association 
between diabetes and Gleason sum ≥7 in the overall sample or either race-group. Some 
studies only reported association between diabetes and a higher Gleason sum cut-point (i.e. 
Gleason sum ≥ 8). Therefore we examined the association using this higher cut-point 
[22,25]. The higher cut-point did not impact our results, and no significant associations were 
observed in either race-group (data not shown).
Among the two studies that looked at race differences, Mitin et al. included men treated with 
radiation between 1991 and 2010 and Jayachandran et al. included men treated with RP 
between 1988-2008. Our study, by contrast, included men diagnosed with CaP between 
2004-2009. The FDA did not approve use of PSA as a screening test in asymptomatic men 
until 1994 [31]. Thus Mitin et al. and Jayachandran et al. included men from the pre-PSA 
and PSA screening eras, while our study sample came entirely from the PSA-screening era. 
Studies that include men from the pre-PSA screening era may be more likely to detect a 
positive relationship between diabetes and CaP aggressiveness at diagnosis as a larger 
proportion of men were diagnosed with high aggressive (later stage) CaP in the pre-PSA 
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screening era. We observed a consistent, strong inverse association between a positive 
history of PSA or DRE screening prior to CaP diagnosis and high aggressiveness CaP at 
diagnosis in the overall sample (OR: 0.42, 95% CI: 0.31, 0.59), Whites (OR: 0.40, 95% CI: 
0.22, 0.74), and Blacks (OR: 0.43, 95% CI: 0.29, 0.63). Neither of the other two studies that 
examined race differences adjusted for CaP screening history [13,22].
Given the close relationship between diabetes and obesity, we investigated the role of 
obesity, independent of diabetes, on CaP aggressiveness. This analysis builds on a previous 
PCaP study that found obesity, not adjusted for diabetes, was associated with high 
aggressive CaP in Whites [Obese (OR: 2.00; 95% CI: 1.13, 3.54), Severely obese (OR: 2.09; 
95% CI: 1.06, 4.14)] but not Blacks [Obese (OR: 1.38; 95% CI: 0.85, 2.23), Severely obese 
(OR: 1.71; 95% CI: 1.00, 2.90)] [23]. Our results, which were consistent with previous PCaP 
reports, showed that obesity, independent of diabetes, was positively associated with our 
composite measure of high aggressive CaP in Whites, but not in Blacks. Obesity, 
independent of diabetes, was associated with Gleason sum ≥ 7 both in the overall sample 
and Whites. The association observed in the overall sample is likely driven by Whites, since 
no association was observed with obesity, independent of diabetes, and Gleason sum ≥ 7 in 
Blacks.
Our results are consistent with those observed in an earlier study utilizing the SEARCH 
database [19]. This study reported that moderate and severe obesity were significantly 
associated with pathologic Gleason sum ≥7 in Whites (OR: 2.35; 95% CI: 1.12, 4.91), but 
not Blacks (OR: 1.48; 95% CI: 0.71, 3.12) [19]. Spangler et al., by contrast, reported that 
obesity was not associated with Gleason sum in Whites or Blacks [32]. This inconsistency 
may result from Spangler et al. having a study sample that was derived from a single, 
academic health system that may not be as representative as population-based samples [32].
Our results suggest the impact of obesity may vary across race, so we examined prevalence 
differences to further elucidate the role of race. This adds to the current literature, which is 
largely limited to measures of association. Prevalence differences were consistent with the 
direction of association for ORs. We found that obesity, independent of diabetes, was 
associated with a 7% increase in the prevalence of high aggressive CaP in Whites and no 
significant difference was observed in Blacks.
Our results show differing associations for diabetes and obesity with high aggressive CaP. 
This finding highlights the complex disease profile of diabetics. The inverse association 
between diabetes and risk of developing CaP has been well established [3-10]. Several 
possible underlying reasons have been suggested for this inverse association, and a 2012 
review by Pierce summarized many of these reasons [14]. Insulin is a known growth factor 
for CaP, and it is hypothesized that the lower insulin levels in diabetics may slow the 
development of incident CaP [11]. However, the changing insulin, testosterone, and glucose 
levels over the diabetes disease-course complicates any potential association between 
diabetes and CaP aggressiveness among men who have already been diagnosed with CaP 
[11,12]. Early stages of diabetes are marked by hyperinsulinemia while in later stages of 
diabetes there is decreased insulin production [14]. Moreover, diabetes is also associated 
with lower testosterone levels [33,34]. In contrast to traditional understanding, lower 
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testosterone levels have recently been shown to be associated with CaP aggressiveness 
[34-39]. However, there is some evidence that also suggests testosterone levels may 
subsequently increase with increasing diabetes duration [11,40,41]. This finding is further 
complicated by the fact that the ratio of sex hormone binding globulin (SHBG) to 
testosterone has also been show to increase with the duration of diabetes, thereby reducing 
the free testosterone available as diabetes progresses [11,14]. As such, depending on 
diabetes duration, how well diabetes is controlled, diabetics may have high insulin levels and 
low testosterone levels, creating an environment that promotes the growth of high aggressive 
CaP.
In this study, however, we did not find an association between diabetes and high aggressive 
CaP. Obesity, independent of diabetes, was associated with high aggressive CaP in Whites. 
There are several possible mechanisms by which obesity may impact CaP aggressiveness 
independent of diabetes. First, obesity has been associated with benign prostatic hyperplasia 
(BPH) [6,42]. Although BPH does not itself increase the risk of CaP, it is possible that it is 
harder to detect CaP in an enlarged prostate [6]. Second, obesity is also associated with 
lower PSA levels [16]. Given that high PSA levels are the primary reason for prostate biopsy 
referral, lower PSA levels could result in delayed referrals and CaP detection. Third, obesity 
can result in less effective digital rectal exams (DRE), another important CaP screening test 
[43]. Factors such as these can all contribute to the diagnosis of CaP at a later, more 
advanced (aggressive) stage. It is possible that Black men were more likely to have CaP 
detected at a later, more advanced (aggressive) stage, independent of these obesity-related 
factors. Our data suggest that this is possible. Blacks with a normal BMI were more likely to 
have high aggressive CaP (22%) than Whites with a normal BMI (12%) in our study sample. 
The prevalence of high aggressive CaP in obese Whites is 20%. This prevalence is lower 
than the prevalence of high aggressive CaP in Blacks with a normal BMI. This could 
explain, in part, why we observed a significant association only in Whites. Our findings 
suggest that obesity may increase the prevalence of high aggressive CaP only when the 
baseline prevalence of high aggressive CaP is relatively low.
Finally it is important to note that obese men are at increased risk for both hyperinsulinemia 
and lower testosterone levels even if they have not been diagnosed with diabetes [44,45]. 
Both these factors can contribute to CaP aggressiveness at diagnosis. Specifically, insulin-
like growth factor (IGF-I), a possible CaP mitogen, is increased in men with 
hyperinsulinemia [46].
A key strength of our study is that it is a population-based study of both Whites and Blacks 
diagnosed with CaP. PCaP is a large, well-characterized, study sample from the PSA 
screening era with detailed epidemiologic, interview, and clinical data, which allow for 
analytic adjustment for factors such as CaP screening history. To our knowledge, previous 
studies that examined racial differences in the association of diabetes and CaP 
aggressiveness at diagnosis were not population-based, encompassed both the pre-PSA and 
PSA screening eras, did not adjust for CaP screening history, and were limited to patients 
receiving a single treatment modality. Thus our results may provide a more representative 
assessment of diabetes and CaP aggressiveness at diagnosis, and therefore may be 
generalized to a broader population of both Blacks and Whites with CaP and diabetes. 
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According to the National Health and Nutrition and Examination Survey (NHANES), 33.6% 
of non-Hispanic White adult men and 37.5% of non-Hispanic Black adult men are obese in 
the U.S. [47]. This is similar to the prevalence of obesity in our study sample, where 37.8% 
of Whites and 39.8% of Blacks are obese. Moreover, estimates by the Centers for Disease 
Control and Prevention (CDC) suggest that among men aged 65-74, in the U.S., the diabetes 
rate is 22.3% for Whites and 29.6% for Blacks [48]. This estimate is similar to the diabetes 
prevalence observed in our study: 21.9% of Whites and 31.7% of Blacks aged 65-74 report 
having diabetes.
Our study used self-reported diabetes and therefore has some limitations. An Atherosclerosis 
Risk in Communities study (ARIC), reported that the sensitivity of prevalent self-reported 
diabetes ranges from 58.5% to 70.8% and the specificity ranges from 95.6% to 96.8% 
depending on the reference definition employed [49]. However, as discussed above the 
prevalence of diabetes in our study sample is representative of national estimates. Another 
potential limitation of our diabetes measure is that we do not know when research subjects 
were diagnosed and cannot evaluate the duration of diabetes exposure, or the severity of 
disease among diabetics, or how well diabetes was controlled. In addition, Black research 
subjects were more likely than White research subjects to be excluded from our analytic 
sample due to missing exposure, outcome, or covariate information. However, despite this 
limitation we retained 87% of Blacks and 94% of Whites in our analytic sample, and almost 
half our analytic sample consisted of Black men.
The PCaP study allowed us the unique opportunity to make population-based estimates of 
the association between diabetes and CaP aggressiveness at diagnosis, and to specifically 
examine this association in a significant number of Black men.
Conclusion
Our results suggest that diabetes may not be associated with CaP aggressiveness at diagnosis 
in men with CaP. Our results further suggest that association of obesity with CaP 
aggressiveness in men diagnosed with CaP may by limited to Whites. Future studies with 
large numbers of both Whites and Blacks with detailed information on diabetes duration and 
management are needed to further elucidate any racial differences that may exist between in 
CaP aggressiveness.
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Table 1
PCaP research subject characteristics
All research Subjects (n= 2049 ) Whites (n=1058 ) Blacks (n=991)
Age years (Mean, SD) 63.0 (7.9) 64.1 (7.9) 61.7 (7.8)
Screening History (n, %)a
    Yes 1838 (89.7) 996 (94.1) 842 (85.0)
    No 211 (10.3) 62 (5.9) 149 (15.0)
Study Site
    North Carolina 973 (47.5) 504 (47.6) 469 (47.3)
    Louisiana 1076 (52.5) 554 (52.4) 522 (52.7)
Education (n, %)
    Less than high school 399 (19.5) 100 (9.5) 299 (30.2)
    High school graduate or some college 1032 (50.4) 497 (47.0) 535 (54.0)
    College graduate or above 618 (30.2) 461 (43.6) 157 (15.8)
BMI (n, %)b
    Normal 374 (18.3) 172 (16.3) 202 (20.4)
    Overweight 881 (43.0) 486 (45.9) 395 (39.9)
    Obese 794 (38.8) 400 (37.8) 394 (39.8)
Diabetes (n, %)c
    Yes 443 (21.6) 177 (16.7) 266 (26.8)
    No 1606 (78.4) 881 (83.3) 725 (73.2)
CaP Aggressivenessd
    Low 1045 (51.0) 586 (55.4) 459 (46.3)
    Intermediate 638 (31.1) 310 (29.3) 328 (33.1)
    High 366 (17.9) 162 (15.3) 204 (20.6)
aScreening history was based on self-report and defined as having at least one PSA or DRE prior to CaP diagnosis.
b
Research subjects were categorized as normal (BMI 18.5 to <25), overweight (BMI 25 to <30), or obese (BMI ≥ 30).
c
Based on self-report.
d
High aggressive CaP was defined as Gleason sum ≥8, or PSA >20 ng/ml, or Gleason sum =7 and clinical stage cT3-cT4. Low aggressive CaP was 
defined as Gleason sum <7 and clinical stage cT1-cT2 and PSA <10 ng/ml. All other other cases were defined as intermediate aggressive CaP.
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Table 3
Prevalence differences (PD) and 95% confidence intervals for high aggressive CaP
All Research Subjects (n=2049) Whites (n=1058) Blacks (n=991)
Proportion with 
outcome (# with 
outcome/# of 
subjects)
Adjusted PDa Proportion with 
outcome (# with 
outcome/# of 
subjects)
Adjusted PDb Proportion with 
outcome (# with 
outcome/ # of 
subjects)
Adjusted PDb
Diabetes
    No 276/1606=0.17 Ref 130/881=0.15 Ref 146/725=0.20 Ref
    Yes 90/443=0.20 0.00 (−0.04, 0.04) 32/177=0.18 0.00 (−0.07, 0.06) 58/266=0.22 0.00 (−0.05, 0.06)
BMI
Normal 64/374 =0.17 Ref 20/172=0.12 Ref 44/202=0.22 Ref
Over-weight 140/881=0.16 −0.01 (−0.05, 003) 64/486=0.13 0.01 (−0.05, 0.07) 76/395=0.19 −0.02 (−0.00, 0.01)
Obese 162/794=0.20 0.04 (0.00, 0.09) 78/400=0.20 0.07 (0.01, 0.14) 84/394=0.21 0.01 (−0.06, 0.08)
a
Included diabetes, age in years, race, screening history, study site, education, and BMI
b
Model included diabetes, age in years, screening history, study site, education, and BMI
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